Outbreak and Postnatal Antibiotic Exposures Drive the Development Trajectory of the Nasopharyngeal Microbiota in the First Year of Life

Polona Rajar[1,2]†, Achal Dhariwal[2]†, Gabriela Salvadori[2], Heidi Aarø Åmdal[2], Dag Berild[3,4], Ulf R. Dahle[5], Drude Fugelseth[1,4], Gorm Greisen[6], Ulrik Lausten-Thomsen[6], Ola Didrik Saugstad[7], Fernanda Cristina Petersen[2]*, Kirsti Haaland[1]*

[1] Department of Neonatal Intensive Care, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

[2] Institute of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway.

[3] Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.

[4] Institute of Clinical Medicine, Faculty of Medicine, Oslo University, Oslo, Norway.

[5] Centre for Antimicrobial Resistance, Norwegian Institute of Public Health, Oslo, Norway

[6] Department of Neonatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

[7] Department of Pediatric Research, University of Oslo, Oslo, Norway.

† These authors contributed equally: Polona Rajar, Achal Dhariwal.

* Correspondence:

Kirsti Haaland

Department of Neonatal Intensive Care Unit Ullevål,

Oslo University Hospital, Oslo, Norway

Tel: +47-22117622

Email: uxkila@ous-hf.no

Fernanda Cristina Petersen

Institute of Oral Biology

Faculty of Dentistry,

University of Oslo, Oslo, Norway

Tel: +47-22840312

E-mail: f.c.petersen@odont.uio.no

ABSTRACT

Early exposure to antibiotics and prolonged hospitalization in preterm infants may perturb microbiome development and contribute to adverse health outcomes. Although nasopharyngeal microbiomes are linked to respiratory infections, their early development is underexplored and often assessed with 16S rRNA sequencing, which lacks species resolution. Here, we investigated nasopharyngeal microbiota dynamics in 66 preterm infants by performing deep shotgun metagenomics on 369 nasopharyngeal aspirates collected from birth until 6 months corrected age (~7-10 months chronological age). The nasopharyngeal microbiota evolved dynamically, exhibiting age-structured and individualized patterns shaped by postnatal antibiotic exposure and hospitalization. Early-life antibiotic exposure (ampicillin + gentamicin) had transient but significant effects on microbial diversity, composition, stability, and community dynamics. Conversely, an unexpected NICU outbreak left a lasting signature, with persistent *S. marcescens* carriage observed at 6 months corrected age, which our machine learning algorithm accurately predicted based on microbiome composition in the first days of life. A *S. marcescens*-dominated community type was present in 45% of total samples and exhibited remarkable stability over time, with minimal transitions to other types regardless of antibiotic exposure. These findings underscore the need for deeper insight into how antibiotics and potential outbreaks can lead to alterations in microbiome trajectories, with possible long-term health implications.

Keywords: whole metagenomic sequencing, nasopharyngeal, respiratory, microbiome, preterm birth, hospital outbreak, antibiotics

INTRODUCTION

Microbial colonization after birth is a dynamic process, influenced by environmental and host factors, which holds significant implications for long-term health [1-3]. Most of the current knowledge originates from studies on the intestinal microbiota, leaving a knowledge gap regarding the microbiota development in other body niches, particularly in the respiratory tract, where infections are notably common and sometimes critical [4-6].

Immediately after birth, the upper respiratory tract mucosa is rapidly colonized by microbes originating from mothers' genito-rectal, skin and oral flora, as well as from the surrounding environment. This initial colonization is followed by an increase in bacterial abundance and a shift towards distinct bacterial communities within weeks [3, 7, 8]. For term infants, the nasopharyngeal microbiota further differentiates towards stable microbial profiles by six months of age, influenced by factors such as the mode of delivery, nutrition regime, and antibiotic therapy [3, 6, 7, 9]. Timed signals from the respiratory microbiota are necessary for the infant's immune system maturation [10-13]. Alterations in airway microbiota during this critical developmental phase has been linked to severity and susceptibility to respiratory diseases later in life, such as asthma, otitis media, and respiratory syncytial virus infections [14-19].

Preterm infants are particularly vulnerable due to the development of inflammation and infection-related pathologies in the respiratory tract, even without confirmed neonatal lung injury [20-23]. For preterm infants, disruption in microbiota development may pose additional risks, exacerbated by prolonged hospitalization and early antibiotic treatment [2, 24]. Both factors dramatically influence the microbial ecological succession in preterm infants, though their effects on non-intestinal sites remain less understood. In Norway, 77% of infants born at gestational age (GA) <32 weeks are exposed to antibiotics during their first week of life, and

75% are treated with antibiotics within 72 hours after birth due to suspected early onset neonatal

sepsis (EONS) [25].

To date, research on the respiratory microbiome has primarily utilized 16S rRNA amplicon

sequencing. This method, however, lacks the species-level resolution necessary to distinguish

between commensals and potential pathogens [20]. This gap in knowledge is largely attributed to

the challenges associated with low microbial biomass and the high content of human DNA in

nasopharyngeal samples, which complicates the retrieval of sufficient microbial DNA for non-

targeted sequencing using shotgun metagenomics [26]. To address these challenges, we recently

developed and optimized a methodology that enabled us to perform an in-depth analysis of the

nasopharyngeal resistome in preterm infants [27, 28]. Here, we focus on the developmental

dynamics of the nasopharyngeal microbiome in preterm infants and explore the impact of

different clinical variables and exposures on its trajectories and maturation.

MATERIALS & METHODS

Study design and sample collection

Between July 2019 and January 2021, we approached parents within 48 hours after birth of all

infants with a gestational age from 28 weeks 0 days to 31 weeks 6 days who were born at or

transferred to the Ullevål Neonatal Intensive Care Unit (NICU), a tertiary NICU at Oslo

University Hospital. Patients' metadata were collected from the electronic records. We divided

infants into three groups (Table 1): "Only Early Antibiotics" ($n = 24$), "Other Antibiotics" ($n =$

21) and "Antibiotic Naive" ($n = 21$). Infants in the "Only Early Antibiotics" group were treated

with intravenous ampicillin and gentamicin due to increased risk for early-onset neonatal sepsis

(EONS), initiated within 24 hours after birth and discontinued after a mean (SD) duration of 4

(2) days. The "Other Antibiotics" group received different combinations of either early

antibiotics (initiated within 72 hours after birth); late antibiotics (initiated later than 72 hours

after birth); and/or antibiotics after discharge (intravenous or per oral route). Five infants

received antibiotics in the period between discharge from the NICU and six months corrected

age. The "Antibiotic Naive" group included infants who did not receive any antibiotics from

birth until 6 months corrected age.

Nasopharyngeal aspirates (NPAs) were obtained within 48 hours at six time points: day of life

(DOL) 0 (= day of birth), DOL 7, DOL 14, DOL 28, DOL 56 or discharge and at six months

corrected age [28]. Samples were stored at -80°C in 20% glycerol (2 ml) solution until further

processing in the laboratory. Throughout all further steps, samples belonging to the same infant

were processed concomitantly.

Metagenomic DNA extraction

Metagenomic DNA extraction was performed using standard operating procedures published

previously [28] with some minor modifications (Method Supplement). After host DNA removal

(MolYsis™ Basic5, Molzym), all samples were spiked with 20 µl of Spike-in Control II Low

Microbial Load (Catalog D6321 & D6321-10, ZymoBIOMICS™, Irvine, CA), immediately

followed by DNA extraction (MasterPure™ Gram Positive DNA Purification Kit, Epicentre).

Zymo Femto™ Quantification kits (ZymoBIOMICS™) were used to quantify human (Zymo

E2005) and microbial DNA (Zymo E2006) in all extracted samples with real time qPCR.

Further, Nextera DNA Flex kit (Illumina Inc., San Diego, CA) was used for metagenomic

library preparation following manufacturer's instructions. Extracted metagenomic DNA was

eluted in 35 µl, quantified using Qubit™ dsDNA HS kit on a Qubit 4.0 Fluorometer (Invitrogen,

Thermo Fisher Scientific, Waltham, MA) and stored at -80°C for up to four weeks before

further processing.

Bacterial and host DNA quantification with real time qPCR

Zymo Femto^{TM} Quantification kits (ZymoBIOMICS™) were used to quantify human (Zymo

E2005) and microbial DNA (Zymo E2006) in all extracted samples, according to the

manufacturer's instructions. Used sample volume was 1 μl.

Controls for low biomass samples

Six aliquots of 20 µl Spike-in Control II (ZymoBIOMICS™) were extracted with MasterPure™

Gram Positive DNA Purification Kit (Epicentre) in two independent experiments and used as a

positive control (expected yield 0.4 ng). One glycerol saline solution sample from each batch

prepared for the cryopreservation of patient samples ($n = 5$) as well as reagent blanks ($n = 5$)

were extracted and used as negative controls. The DNA yield from negative controls was

extremely low or undetected ($n = 10$; mean $= 0.00043$ ng/µL), as measured by RT-qPCR.

Metagenomic Library Preparation and Sequencing

Nextera DNA Flex kit (Illumina Inc., San Diego, CA) was used for library preparation

following manufacturer's instructions. Input yield was set to 10 ng DNA according to Qubit

results, and all available extracted DNA was used in samples that yielded less than 10 ng

according to both Qubit and PCR measurements. Twenty-four samples from 16 infants were

excluded from library preparation due to negative 16S rRNA qPCR values, determined by

subtracting their bacterial DNA yield from the average yield of positive spike-in controls

(Supplementary Table E1).

Twelve PCR amplification cycles were used for metagenomic library preparation as per the

producer's recommendations. Library concentration and purity were measured using Qubit^{TM}

dsDNA HS kit (Invitrogen) and Bioanalyzer 2100 (Agilent, Santa Clara, CA). Libraries of

remaining 345 NPA samples proceeded to WMS in one pool with 5 nM concentration (Figure

1B). Three samples with insufficient sequencing reads after contaminant removal were also

excluded (Supplementary Table E5). Furthermore, for four infants with multiple samples

available at the same time points, only one sample per time point was retained, leading to the

exclusion of six additional samples before downstream analysis. Twenty-two of the 25 samples

excluded before WMS analysis belonged to infants exposed to postnatal antibiotics ($p < 0.05$)

(Supplementary Table E1). Libraries of positive ($n = 6$) and negative controls ($n = 10$)

proceeded to WMS in one pool with 9.4 nM concentration. Details on sample inclusion and

exclusion at various stages, from sampling to analysis, are provided in Supplementary Table

E1.

Whole metagenome sequencing (WMS) was conducted at the Norwegian Sequencing Centre

(Oslo, Norway), on a NovaSeq S4 platform (Illumina Inc.) using a paired-end sequencing

approach with a targeted read length of 150 bp in high-output mode.

Bioinformatics processing and microbiome profiling

FASTQC (v.0.11.9) was used to assess the quality of raw and clean reads [29]. Quality and adapter

trimming, as well as quality control were performed with Trim galore (v.0.6.1) [30]. All reads

were aligned with human reference genome (GRCh38) and human DNA sequences were

removed using Bowtie2 (v.2.3.4.2) [31]. MetaPhlAn 3.0 [32] was used for taxonomic microbiome

profiling of the remaining clean, high-quality reads, using a customized database by adding

clade-specific marker gene from the mock species (*q=0.05*).

Statistical analysis and data visualization

Details regarding statistical analysis of cohort demographics, 16S rRNA qPCR results and

downstream analysis of WMS data are described in the Method Supplement. Downstream

analysis was conducted in R (v.4.2.1) within RStudio (v.2022.07.2+576) [33, 34]. Figures were

created mainly created using ggplot2 (v.3.4.0) package [35] and GraphPad Prism 9.4.1(458)©

GraphPad Software, LLC (Boston, MA, USA).

RESULTS

Study cohort characteristics and overview of sequencing results

We obtained 369 NPA samples from 66 infants at six sampling time points between birth and six months corrected age (Figure 1), including 108 samples from 21 infants not exposed to any postnatal antibiotics (Figure S1A). Infants exposed to postnatal antibiotic (n = 45) had lower GA and birth weight (BW), and their mothers were more often treated with antibiotics during pregnancy (Table 1). The average (SD) early antibiotic (ampicillin and gentamicin) treatment duration was 4 (2) days. None of the infants had a positive blood culture obtained prior to initiation of early antibiotics, and 13 had a positive blood culture prior to initiation of late antibiotics.

In total, 12.13 billion raw sequencing reads were generated from NPA samples, with an average of 35 million (M) reads per sample (range: 2.55–93 M) (Supplementary Table E2). Of the total reads, 99.09–99.99% survived quality filtering and trimming across all samples. In contrast, the average number of raw sequencing reads detected in negative control samples was ~2.5 logs lower (mean: 0.15 M; range: 24,113–355,861) compared to nasopharyngeal samples (Supplementary Table E2). On average, 55% of quality-filtered reads (range: 0.86%–98.6%) were associated with the human genome. After human contamination removal, an average of 6 M high-quality clean reads per sample (range: 439–24 M) were assigned to bacteria (Supplementary Table E2). A total of 28 microbial species, including three ZymoBIOMICS spike-in species, were identified as microbial contaminants and excluded from the raw microbial abundance tables (Supplementary Table E5). Overall, 336 nasopharyngeal samples collected from 66 preterm infants were included in downstream analysis, containing 537 species distributed across 13 bacterial phyla.

Characterization of nasopharyngeal microbial load, composition, and dynamics in preterm infants

Firstly, we quantified total bacterial load in nasopharyngeal samples from preterm infants using 16S rRNA gene-targeted qPCR. Using a generalized linear mixed-effects model (GLMM) corrected for individual variation and age, we observed a significant increase in absolute bacterial abundance up to time point 4 compared to the initial sample (time point 1) (Tukey HSD post hoc test: *p.adj* < 0.05; Figure 2A). This increase was followed by stabilization and a slight declining trend observed at 6 months corrected age. The mean absolute bacterial abundance across infant groups was lowest at time point 1 (mean log 16S qPCR: -1.15 ng), indicating low bacterial loads in the nasopharynx of preterm infants at birth (Figure 2B). Further, infants exposed to "Other antibiotics" had significantly lower bacterial loads at time point 3 compared to those in the "Only Early antibiotics" group (pairwise Wilcoxon test: *p.adj* = 0.012; Figure 2B).

We next characterized the microbial community composition in the developing nasopharyngeal microbiome using shotgun metagenomic sequencing. Absolute bacterial abundance (measured by qPCR) showed no significant correlation with the number of bacterial reads (Pearson: R = 0.09, *p* = 0.10; Figure S1C). *Proteobacteria* (mean: 53.3%; SD: 13.5%) and *Firmicutes* (mean: 38.1%; SD: 12.1%) were the dominant phyla, followed by *Actinobacteria* (mean: 6.8%; SD: 2.46%), *Fusobacteria* (mean: 1.2%; SD: 1.69%), and *Bacteroidetes* (mean: 0.6%; SD: 0.59%) across all groups and time points (Figure S2).

At the genus level, the five most abundant bacteria were *Serratia* (mean: 26.73%; SD: 10.93%), *Streptococcus* (mean: 23.45%; SD: 9.50%), *Staphylococcus* (mean: 17.08%; SD: 9.18%), *Gemella* (mean: 7.16%; SD: 4.09%), and *Corynebacterium* (mean: 3.50%; SD: 2.49%) (Figure 2C). *Serratia* predominated in the naive group (mean: 38.18%; SD: 16.8%), *Streptococcus* in

the "Only Early Antibiotics" group (mean: 25.36%; SD: 7.19%), and *Staphylococcus* in the "Other Antibiotics" group (mean: 24.69%; SD: 14.60%) (Figure 2D). At time point 1, *Serratia* had the highest mean relative abundance (45.72%), followed by *Streptococcus* (14.85%) and *Staphylococcus* (12.68%). *Staphylococcus* and *Streptococcus* were the most prevalent genera, detected in over 90% of samples.

Streptococcus mitis and *Staphylococcus epidermidis* were the most prevalent species, identified in over 89% of the samples. The most abundant species were *Serratia marcescens* (mean: 23.76%; SD: 9.66%), followed by *S. epidermidis* (mean: 18.48%; SD: 5.51%), *S. mitis* (mean: 14.13%; SD: 7.04%), *Gemella haemolysans* (mean: 6.56%; SD: 7.04%), and *Staphylococcus aureus* (mean: 6.44%; SD: 4.21%) (Figure 2E). However, no species exhibited dominance (>50% relative abundance) in more than 10% of samples, irrespective of antibiotic exposure. *S. epidermidis* increased in relative abundance until time point 3, after which *S. aureus* became the dominant *Staphylococcus* species. *S. mitis* remained the most abundant *Streptococcus* species across all time points (Figure 2E). At six months corrected age (time point 6), the microbiome composition was discernible from earlier time points. In the "Only Early Antibiotics" (mean: 18.67%) and "Other Antibiotics" (mean: 15.88%) groups, *Dolosigranulum pigrum*, often associated with health, emerged as one of the dominant species, while *Moraxella catarrhalis*, linked to respiratory health risks, predominated in the naive group (mean: 25.28%) (Figure 2F). Both *D. pigrum* and *M. catarrhalis* had the highest mean relative abundances at time point 6 across all groups. Additionally, *S. aureus* accounted for less than 0.5% to the total mean relative abundance in groups dominated by *M. catarrhalis* at 6 months corrected age.

Postnatal antibiotic exposure affects the nasopharyngeal microbiome diversity, composition and stability

Metagenomic analysis revealed a gradual increase in species-level α-diversity (measured using

Shannon index) over time (time point: 1-4) in the nasopharyngeal microbiome before

plateauing across infants (time point: 4-6) (Figure 3A). To determine which clinical variables

(in Supplementary Table E6) were associated with microbiota diversity (Shannon), we used a

GLMM approach, including subject as a random effect to account for individual variation. No

clinical variable, other than age (Tukey HSD post hoc test: *p.adj* < 0.05), was significantly

associated with infant nasopharyngeal microbiome diversity. When stratified by postnatal

antibiotic exposure, we observed a similar trend of increasing α-diversity over time, stabilizing

at later time points in the "Other Antibiotics" and "Naive" groups. However, in the "Only Early

Antibiotics" group, we noticed significantly lower α-diversity at time points (time point 2 and

3) mostly coinciding with the discontinuation of ampicillin and gentamicin (Tukey HSD post

hoc test: *p.adj* < 0.05; Figure 3B). These changes remained significant even after correcting for

age, suggesting a potential effect of early antibiotic administration on the nasopharyngeal

microbiome.

Next, we performed β-diversity analysis to assess the impact of postnatal antibiotic use on the

overall nasopharyngeal microbial community composition at each time point. Here, we

explored the effect of early, late and after discharge antibiotics separately. At time point 1, no

significant differences were detected in the composition between treatment groups

(PERMANOVA-test: R^2 = 4.33%, *p.adj* = 0.189; Figure S3A). The effect of early antibiotics

was most pronounced in the first samples collected after the cessation of early antibiotic

treatment *i.e.,* time point 2 (R^2 = 2.74%, *p.adj* = 0.016; Figure 3C), with significant differences

observed in the composition of infants exposed to "Only Early antibiotics" compared to

antibiotic-naive infants (R^2 = 4.42%, *p.adj* = 0.018; Figure S3B). Further, our results from

differential abundance analysis revealed a significant reduction in *Staphylococcus argenteus*

and *Staphylococcus aureus* in the "Only Early Antibiotics" group compared to the "Naive"

group (ANCOM-BC2: *p.adj* < 0.05), supporting the observed compositional differences.

However, this effect of early antibiotics was transient and was not evident at any subsequent

time points up to 6 months corrected age (PERMANOVA: all *p.adj* > 0.05; Figure S3C-F).

When examining other postnatal antibiotic regimens, we found a minor but significant effect of

late antibiotics following treatment at time point 3 (R^2 = 2.91%, *p.adj* = 0.014; Figure 3D). On

the other hand, antibiotics administered after discharge from the NICU did not significantly

affect the microbiome composition at six months corrected age (R^2 = 2%, *p.adj* = 0.262).

We also investigated whether microbial community stability differed among treatment groups

over time. Community stability, measured by Aitchison dissimilarity between consecutive time

points within each infant, was highest in the "Naive" group (mean dissimilarity = 39.4), which

showed significantly greater temporal stability compared to the "Other Antibiotics" group

(mean dissimilarity = 43.5) over the study period (pairwise Wilcoxon test: *p.adj* = 0.003; Figure

3E, F). Across all groups, the lowest stability (highest dissimilarity) was observed between time

points 5–6, potentially driven by a combination of changing environmental, infant-related,

perinatal, and healthcare-associated factors. During the antibiotic discontinuation period (time

points 2–3), infants in the "Only Early Antibiotics" group showed a tendency toward greater

stability compared to the "Naïve" group (mean dissimilarity = 36.6 vs. 38.7), though the

difference was not statistically significant (pairwise Wilcoxon test: *p.adj* = 1; Figure 2F).

Notably, significant differences in stability between time points 5–6 and earlier post-antibiotic

periods were observed only in this group (pairwise Wilcoxon test, *p.adj* < 0.05; Figure S4). This

suggests that early antibiotic exposure drives microbial communities to become more similar

across individuals, reflecting a homogenizing effect on nasopharyngeal microbiota

development.

Factors influencing the nasopharyngeal microbiota development in preterm infants

To identify drivers of infant nasopharyngeal microbiota composition, we used PERMANOVA

tests (all *p.adj* ≤ 0.001) based on Aitchison distance and visualized the results using Principal

component analysis (PCA) of CLR-transformed data from samples collected from preterm birth

to 6 months corrected age (~7-10 months chronological age). Inter-individual variation had a

pronounced effect on nasopharyngeal microbiota composition, explaining 33.08% of the

community variation (PERMANOVA: R^2 = 33.08%, *p.adj* = 0.001, Figure S5A), highlighting

the highly individualized nature of longitudinal microbiota changes and underscoring the

importance of accounting for inter-individual variation in microbiome studies. Among clinical

variables, postnatal age was significantly associated with overall nasopharyngeal microbial

community composition across the infant cohort. Postmenstrual age (PMA) exerted a greater

influence on overall microbiota composition (R^2 = 7.7%, *p.adj* = 0.001; Figure S5B) compared

to chronological age, represented by sampling time points (R^2 = 6.33%, *p.adj* = 0.001; Figure

4A), and days of life (DOL) (R^2 = 2.75%, *p.adj* = 0.001; Figure S5C), while adjusting for inter-

individual variation.

Mode of birth (R^2 = 0.36%, *p.adj* = 1) and antibiotic treatment (during pregnancy, birth, and

postnatally), including its duration, did not significantly influence microbiota composition

(Supplementary Table E3). Additionally, baseline variables that differed between the three

antibiotic exposure groups, such as gestational age (R^2 = 1.97%, *p.adj* = 1), birth weight (R^2 =

1.31%, *p.adj* = 1), and duration of ruptured membranes (R^2 = 0.30%, *p.adj* = 1), were not

significantly associated with microbial community composition during the first ~7-10 months

of life (Supplementary Table E3).

To further explore whether infant nasopharyngeal microbiota maturation is ubiquitously

associated with age, we employed the Random Forests machine learning algorithm to regress

microbial species relative abundances against the chronological age of preterm infants, as

previously described [36]. A total of 24 taxa were identified as the minimum set required for

accurate age prediction (Figure 4B). Using these 24 most informative age-discriminatory taxa,

we trained, refined, and validated a model to characterize nasopharyngeal microbiota

development in preterm infants. The taxa most strongly associated with age in the

nasopharyngeal microbiota were *Dolosigranulum pigrum*, *Granulicatella elegans* and

Moraxella catarrhalis (Figure 4C). This finalized sparse model was then applied to predict

infant chronological age based on the relative abundances of these 24 taxa, producing a

microbiota-derived predicted age that reflects microbiota maturity. A strong linear relationship

was observed between microbiota age and chronological age of preterm infants (Pearson: R =

0.97, $p < 0.0001$, Figure 4D), confirming the model's accuracy in predicting preterm infant age.

However, in infants exposed to postnatal antibiotics, predicted microbiota age showed a non-

significant tendency to lag behind chronological age at 6 months corrected age (Figure 4D).

Developmental trajectory of the infant nasopharynx microbiota in early life based on

community types

Using the Dirichlet multinomial mixture (DMM) method, we identified four optimal

community type clusters (CT1-4) in the nasopharyngeal microbiota of all preterm infants based

on its composition (Figure S6A). These clusters accounted for 45.2% (CT1), 38.7% (CT2),

8.6% (CT3), and 7.5% (CT4) of all the samples (Figure 5D, E). These community types were

mainly characterized by variations in the relative abundances of four bacterial genera:

Streptococcus, *Serratia*, *Staphylococcus*, and *Gemella* (Figure 5B, Figure S6B). CT1 and CT4

were predominated by *Serratia* and *Staphylococcus*, respectively, while CT2 and CT3 exhibited

higher abundances of both *Streptococcus* and *Gemella* (Figure 5B). Notably, CT2 had a

significantly higher relative abundance of *Staphylococcus* compared to CT3. These genera

dominated their respective community types with mean relative abundances of 51.8% for

Serratia (CT1), 40.16% (CT2) and 35.27% (CT3) for *Streptococcus*, 14.4% (CT2) and 11.5%

(CT3) for *Gemella*, and 21.92% for *Staphylococcus* (CT4).

We also found significant differences in microbial diversity (α-diversity, pairwise Wilcoxon

test: all *p.adj* < 0.05; Figure 5C) and overall composition (β-diversity, PERMANOVA: R^2 =

12.61%, *p.adj* = 0.001; Figure 5A) between all the identified community types. Moreover,

sequencing depth did not differ significantly between community types (pairwise Wilcoxon

test: *p.adj* > 0.05; Figure S6C), suggesting that it was unlikely to influence their separation.

Sampling time point was significantly associated with community type clustering in the "Only

Early Antibiotics" and Naive groups (Fisher's exact test: *p.adj* < 0.05; Figure 5D), while no

such association was observed in the "Other Antibiotics" group (Fisher's exact test: *p.adj* =

0.15; Figure 5D). Additionally, there was no significant difference in community type

clustering when stratified according to antibiotic exposure group (Fisher's exact test: *p.adj* =

0.44) (Figure 5E).

Next, we performed a Markov chain-based analysis to quantify the likelihood of transitions

between community types in the early-life nasopharyngeal microbiota of preterm infants. The

modeling revealed distinct transition patterns across treatment groups, with CT1 (*Serratia*-

driven) emerging as one of the most stable (*i.e.,* higher self-transition probability) states (mean

prob. = 0.53), followed by CT2 (0.47) (Figure 5F). Community types were most stable in the

naive group (mean prob. = 0.5) compared to the other groups. However, CT3 and CT4 in the

naive group transitioned more frequently or equally toward CT2 (0.6 and 0.5, respectively)

compared to their self-transition probabilities (Figure 5F). In contrast, in the "Only Early

Antibiotics" group, CT3 (0.6) and CT4 (0.67) transitioned predominantly to CT1, a community

type with the lowest species diversity, underlining our earlier observation that early antibiotic

exposure reduces microbial diversity. This may explain the disappearance of CT3 and CT4

following treatment at time points 2 and 3 (Figure 5D). On the other hand, the "Other Antibiotics" group exhibited lower stability in dominant communities, such as CT1, and more frequent transitions between states (Figure 5F), resulting in greater dynamism. This variability may reflect the influence of different antibiotic regimens within this group. Overall, these findings highlight the pronounced effects of postnatal antibiotic exposures on early-life microbial community dynamics, reducing overall community stability by making transient states less stable and promoting more frequent transitions across communities.

We further leveraged metagenomics sequencing data to investigate functional differences among community types by characterizing their antibiotic resistance (resistome) profiles [27]. Striking differences were observed between the community types. The *Streptococcus*-dominated community type (CT2) exhibited a significantly higher AMR load, reflected in both total ARG abundance and ARG diversity (Shannon index) (pairwise Wilcoxon test: *p.adj* < 0.05; Figure 5G). These findings suggest that *Streptococcus* plays a key role in driving antibiotic resistance within the infant nasopharyngeal microbiome.

Prolonged signature of an outbreak on nasopharyngeal microbiota in preterm infants

A few months into our study, a clinical outbreak with *S. marcescens* was detected in the NICU. Six infants, including three from our study cohort, tested positive for *S. marcescens* in various clinical samples. After two screenings conducted seven days apart on all hospitalized infants, the second screening found no positive nasopharyngeal cultures, and the outbreak was declared over (Figure S7A). Environmental samples were negative, and no source of the outbreak was identified. However, metagenomic analysis of nasopharyngeal aspirate samples revealed persistent carriage of *S. marcescens* in infants hospitalized after the outbreak (Figure 6A). Notably, *S. marcescens*, which was detected early after birth (time point 1), persisted in over 90% of preterm infants across all treatment groups and remained detectable at ~7–10 months

of chronological age (time point 6), extending well beyond hospital discharge (Figure S7B).

Moreover, no significant differences in the abundance of *S. marcescens* were detected among

treatment groups at any time point (Figure 6B).

Further, our analysis revealed that *S. marcescens* emerged as the dominant species, accounting

for the most variation in overall microbiota composition (PERMANOVA: R^2 = 6.76%, *p.adj* =

0.001; Figure 6C). *S. marcescens* showed a significantly higher abundance in samples collected

from infants hospitalized after the outbreak compared to those discharged or transferred to a

different NICU prior to it (pairwise Wilcoxon test: *p.adj* < 0.05; Figure 6D). Although

hospitalization status did not significantly influence the overall nasopharyngeal microbiota

composition in preterm infants (PERMANOVA: R^2 = 1.46%, p.adj = 0.824; Figure 6E), our

cross-sectional analysis revealed significant differences in composition at the first two sampling

time points (time points 1 and 2), with these differences becoming most pronounced by six

months corrected age (time point 6, R^2 = 4.91%, p.adj = 0.001; Figure S7C).

To further analyze the persistent effects of the outbreak, we used a supervised machine learning

algorithm, Random Forest, to predict the presence or absence of *S. marcescens* at six months

corrected age (time point 6) based on microbiome composition in early life (time points 1 and

2). Our model demonstrated high performance, achieving 94.74% and 100% accuracy at time

point 1 and 2, respectively, in classifying *S. marcescens*-positive and *S. marcescens*-negative

groups (Figure S8). These results indicate that the nasopharyngeal microbiome composition in

early life can predict the persistence of *S. marcescens* colonization at six months corrected age.

Overall, these findings suggest that *S. marcescens* establishes a prolonged microbial signature,

likely reflective of its acquisition during the NICU outbreak.

DISCUSSION

The nasopharyngeal microbiota is a critical reservoir for microbes associated with respiratory tract infections, influencing immune development and disease susceptibility in infants [10, 14, 17, 37]. This study provides an unprecedented high-resolution analysis of the longitudinal development of the preterm nasopharyngeal microbiota using deep whole metagenome sequencing. We demonstrated that the nasopharyngeal microbiota development from birth to 6 months corrected age was characterized by dynamic and age-structured communities, with highly individualized patterns influenced by postnatal antibiotic exposure and hospitalization. Early-life antibiotic exposure (ampicillin + gentamicin) had transient but pronounced ecological effects on microbial diversity, composition, stability, and community type transition dynamics. An unexpected *Serratia marcescens* outbreak during the study gave us a unique opportunity to assess its impact on microbiota development by comparing the microbiome before and after the outbreak. We found a persistent outbreak signature that, at ~7–10 months chronological age (6 months corrected age), could be accurately predicted from the nasopharyngeal microbiota composition in the first days of life.

After birth, preterm infants exhibited low bacterial abundance and diversity in the nasopharyngeal microbiota, followed by a sharp increase in the first few weeks and a more gradual rise for up to two months before stabilization. Similar trends have been described for term as well as preterm infants [3, 7, 38, 39], though our metagenomic approach offers enhanced taxonomic resolution at species-level. In addition, samples from postnatal antibiotic-exposed infants were more likely to have low biomass from birth up to 6 months corrected age. Postnatal age was found to be associated with infant nasopharyngeal microbiome diversity, with a significant reduction observed directly upon treatment in the "Only Early antibiotics" group. Infants exposed to "Other Antibiotics" had significantly lower absolute bacterial abundance at

two weeks after birth compared with "Only Early antibiotics" group. Overall, these trends in our results suggest a general suppression of bacterial colonization and diversity, associated with the discontinuation of early and/or late antibiotics in the nasopharyngeal microbiota of infants.

Microbiome development in early life is a dynamic process, and transformations in the nasopharyngeal microbiota are expected, even in antibiotic-naive infants. In our cohort, the nasopharyngeal microbiota of infants was predominantly colonized by four genera: *Serratia*, *Streptococcus*, *Gemella*, and *Staphylococcus*, forming different community types. At the species level, *S. marcescens*, *S. epidermidis*, *S. aureus*, *Gemella haemolysans*, and *S. mitis* were commonly identified during the first two months of life. Carriage of specific bacterial species in the upper respiratory tract, such as methicillin-resistant *Staphylococcus aureus* (MRSA), has been closely linked to increased infection risks for newborns in the NICU [40]. Of particular concern are pathogens identified by the World Health Organization (WHO) as critical priorities due to their potential to cause severe infections and resistance to multiple antibiotics [41]. In our study, among the 20 most abundant species, we identified several on the WHO priority list pathogens, including *Serratia marcescens* that became prominent during the outbreak, alongside *Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae,* and additional species from the Enterobacteriaceae family.

Because shotgun metagenomics enables higher taxonomic resolution than 16S rRNA studies, we were able to distinguish highly relevant pathogens from species generally considered commensals in immunocompetent individuals. For example, most streptococci identified belonged to *Streptococcus mitis* across all ages. *S. mitis* is a close relative of *S. pneumoniae* and is considered a commensal that may provide protection against its pathogenic counterpart [42]. In contrast, *S. pneumoniae*, a human colonizer with high pathogenic potential, appeared at lower abundances, reaching its highest proportion at 6 months corrected age. This timing coincides

with when *S. pneumoniae* typically becomes more common in the nasopharynx of infants [43].

Among the staphylococci, we could distinctly identify *S. epidermidis*, initially more prevalent,

and *S. aureus*, a pathogen of greater concern, which became the dominant species in this genus

after approximately 3 weeks of life. Expanding our understanding of such species-specific

dynamics is relevant as it may help guiding future preventative strategies.

By six months corrected age, the nasopharyngeal microbiome shifted significantly,

characterized by the dominance of *Dolosigranulum pigrum* and *Moraxella catarrhalis*,

alongside the presence of some oral bacteria such as *Neisseria flavescens* and *Veillonella spp.*

While *Corynebacterium* and *Dolosigranulum* are often associated with respiratory health

benefits [3, 6, 44], their scarcity in our cohort may reflect the unique conditions of preterm birth

and the impact of an outbreak. Instead, we observed a high prevalence of *Moraxella* across all

time points, with 16% of samples at 6 months corrected age dominated by this genus, and no

significant differences between antibiotic exposure groups. Although early *Moraxella*

colonization and low abundances of *Corynebacterium* and *Dolosigranulum* may predispose

infants to chronic inflammation [3, 45], some studies suggest that Moraxella-dominant profiles are

associated with community stability and fewer respiratory infections [6]. A longer follow-up of

our cohort may further clarify these dynamics and their impact on future respiratory health

outcomes [16, 46, 47].

Using machine learning, we identified *Dolosigranulum pigrum* and *Moraxella catarrhalis* as

key age-discriminatory species in the nasopharyngeal microbiota of preterm infants, aligning

with 16S rRNA studies that highlight *Dolosigranulum* and *Moraxella* as significant age-

associated taxa [3]. Moreover, for infants who were exposed to postnatal antibiotics, the

development of their nasopharyngeal microbiota seemed to lag slightly behind their

chronological ages at 6 months corrected age, indicating a potential delay in microbiota

maturation due to early antibiotic exposure; however, this observation was not statistically

significant. This trend aligns with prior research on the gut microbiota suggesting that early-

life antibiotic use disrupts microbial succession, with potential immune consequences [48]. In the

respiratory tract, changes in maturation of the nasopharyngeal microbiota have been correlated

with increased risk of respiratory tract infections during the first year of life [3]. Such relationships

indicate that insights into the developmental dynamics of the nasopharyngeal microbiome could

be key in identifying factors contributing to infection susceptibility and shaping strategies to

reduce respiratory health risks in infancy.

Inter-individual variability was the most significant factor influencing nasopharyngeal

microbiome composition, consistent with previous findings in both term and preterm infants [3,

15, 49]. In addition to individual differences, postnatal age also significantly impacted microbiome

composition in our cohort, aligning with earlier studies [3, 7, 50]. However, in contrast to Bosch et

al. [7], we found no significant association between mode of delivery and nasopharyngeal

microbiome composition in the first year of life. Similar findings have been published for the

gut microbiome, with postnatal age having a greater influence than mode of delivery-both

recognized as known factors shaping the microbiome composition of preterm infants [36, 51].

Early-life antibiotic exposure has been linked to several diseases [16, 52, 53]. However, conflicting

results have been reported in the literature regarding the impact of antibiotic exposure on

nasopharyngeal microbiome composition in infants [54]. In our cohort, early antibiotic treatment

(ampicillin + gentamicin) had a pronounced homogenizing effect on the nasopharyngeal

microbiome directly following treatment, characterized by reduced bacterial diversity and

absolute abundance, as well as marked shifts in overall composition and microbiota stability.

Moreover, our statistical modeling of random ecological processes offers a fresh perspective

on how early antibiotic exposure can disrupt microbial colonization dynamics by promoting a

transition from *Staphylococcus* to a *Serratia*-dominated community. This shift may result in the

selection of nosocomial strains (mainly *S. marcescens*), whose resistome contains genes

capable of conferring resistance to the administered antibiotic classes [27]. Our differential

abundance analysis corroborates these findings, showing a significant decrease in

Staphylococcus argenteus and *Staphylococcus aureus* in the "Only Early Antibiotics" group

compared to the "Naive" group directly after treatment at 4 to 9 DOL (time point 2; ANCOM-

BC2: *p.adj* <0.05). In addition to early antibiotic effects, we observed minor yet significant

shifts in taxonomic composition following late antibiotic exposure at 12 to 19 DOL (time point

3). Infants in the "Other antibiotics" group, exposed to multiple classes of antibiotics (Beta-

lactam, Aminoglycoside, Glycopeptides, Nitroimidazole, Lincosamide), exhibited significantly

lower temporal microbiome stability and a higher frequency of transitions between community

types compared to the naive group. This suggests that exposure to multiple antibiotic classes

may further disrupt the natural course of microbiota development typically observed in

antibiotic-naive infants.

Although no discernible effects of postnatal antibiotics on the nasopharyngeal microbiota were

detected by NICU discharge or at 6 months corrected age, even transient alterations to the

infant's microbiome may have lasting consequences. Such changes can increase the risk of

diseases later in life [17], influence immune system development, and promote the selection and

spread of antibiotic resistance genes in both pathogenic and commensal bacteria [36]. This is

particularly concerning, given that leading pathogens commonly found in the nasopharyngeal

microbiota account for the highest global burden of deaths attributable to antimicrobial

resistance [55]. Implementation of stewardship actions focused on optimizing or reducing the

initiation of early antibiotic therapy appears promising and has been adopted in some NICUs,

though not yet for the smallest preterm infants [56, 57].

Besides antibiotics, intensive care procedures such as intubation, feeding tubes and intravenous

lines, may also influence colonization patterns [58]. Additionally, prolonged hospital stays expose

preterm infants to potentially pathogenic bacteria while their immune systems are still

developing [59]. The local NICU environment has been shown to influence the gut, skin

microbiome, and resistome of infants [60]. *S. marcescens*, an opportunistic pathogen prevalent in

NICUs, can cause outbreaks and nosocomial infections in preterm infants [61]. Its persistence

post-hospitalization and outbreak in our study underscores its role as a marker of hospital-

acquired colonization, potentially influencing early-life microbiome development in preterm

infants. This real-time outbreak likely coincided with its NICU introduction, illustrating the

dynamic nature of hospital-acquired infections. The detection of *S. marcescens* was strongly

linked to an outbreak that occurred during the study period. Although the outbreak was

officially declared over after a short interval, our data indicate that *S. marcescens* persisted to

the end of the study. Notably, previous studies do not report *Serratia* in the nasopharyngeal

microbiota of term infants, and in preterm infants, it has been described only in very low

abundance[38]. Understanding its prolonged presence is vital for assessing the long-term effects

of hospital-acquired dysbiosis on microbiota development.

A significant strength of our study lies in the serendipitous timing of the outbreak in conjunction

with our longitudinal study, which gave us a unique chance to analyze its effects on the

nasopharyngeal microbiome. In addition, the study's inclusion of a naive group adds a valuable

control, as comprehensive studies on preterm infants involve not seldom cohorts where all have

been administered antibiotics [62, 63], which is common practice in some hospitals for very and

extremely low-birth-weight newborns [64]. Also, the consistent administration of early

antibiotics, specifically ampicillin and gentamicin, ensures that comparisons are not diluted in

significance due to variability in treatment, as different antibiotics often have distinct impacts

on the microbiota [65]. Moreover, we followed recommended low-biomass research practices for

our nasopharyngeal samples [66], including sequencing negative and positive controls and

rigorous *in silico* contaminant removal to minimize contamination and bias, ensuring reliable

and accurate findings. Infants remained in a controlled NICU environment for most sampling

periods, had no daycare exposure before the final sampling, and followed a consistent

vaccination schedule, minimizing external influences [14, 17]. Additionally, we used

nasopharyngeal aspirates instead of nasal swabs to reduce contamination from the anterior

nostril microbiome [67]. Notably, this is the first study to track the development of the infant

nasopharyngeal microbiome with species-level resolution, offering detailed insights into

microbial dynamics.

However, our study has some limitations. Firstly, we focused on known factors influencing the

microbiome and may have overlooked other relevant variables. Notably, we did not assess

potential microbial sources such as hospital surfaces, healthcare personnel, or maternal

microbiota, which could contribute to infant nasopharyngeal microbiome development. Since

this is a human microbiome study, a causal relationship between antibiotic treatment and the

observed ecological effects cannot be fully established. Confirming causality would necessitate

complementary mechanistic studies, such as those involving animal models. However, our

findings strongly suggest a direct biological impact of antibiotics, as the microbiota

composition in the treatment group showed significant alterations only immediately following

exposure, with effects that gradually diminished over time, even after adjusting for age-related

changes. While there were significant differences in gestational age between infants exposed to

antibiotics and those who were not, our analysis did not reveal a significant association between

gestational age and microbiota composition. This suggests that, although gestational age may

be a relevant factor, it did not impart a notable effect on the microbiome outcomes observed in

our study. The study's single-center design may also limit the broader applicability of our

findings. Additionally, concurrent processing of each infant's samples (all samples in the same

batch) may have reinforced individual microbiome signatures. Despite equimolar library

pooling prior to WMS, variation in raw and bacterial reads was observed. Nonetheless, we

rigorously accounted for inter-individual variation and employed analytical methods that

mitigate sensitivity to sequencing depth while addressing the compositional nature of

microbiome data [68, 69], ensuring the reliability and robustness of our findings.

Overall, this study highlights the significant influences of age, outbreak events, and postnatal

antibiotic exposure on the developmental dynamics of the nasopharyngeal microbiota in

preterm infants. The transient alterations in microbial diversity, composition and stability

observed in response to antibiotic exposure, along with the enduring impact of microbial

signatures from outbreak events, underscore the importance of understanding these factors in

shaping the microbiome in early life. Preterm infants are exposed to multiple factors known to

shape the microbiota across various body niches [70 36 71 72]. There is also growing evidence that

respiratory health outcomes may be influenced by the intestinal and oral microbiota [9, 15, 73].

Future studies are warranted to investigate the interconnected colonization dynamics of these

body niches during infancy. Additionally, ongoing efforts to develop strategies for restoring

microbial balance and minimizing unnecessary antibiotic use during this critical phase of

development represent a valuable pathway for preventing disturbances in microbiota-host

interactions [74, 75], which may have potential implications for health.

Ethical statement

The study was performed in accordance with the Declaration of Helsinki and approved by the Hospital's Data Protection Officer and the Regional Committee for Medical and Health Research Ethics-South East, Norway (2018/1381 REKD).

Consent statement

Written informed consent was obtained from the infant's parents. The participants received no compensation.

Data availability

The metagenomic sequencing data (clean reads *i.e.,* after quality filtering and removal of human DNA) generated from all nasopharyngeal samples are publicly available on the NCBI Sequence Read Archive database under BioProject ID: PRJNA1009231.

Acknowledgments

We would like to thank the parents of participating infants, and the clinical staff at the Neonatal Intensive Care units at Ullevål hospital for their assistance with sample collection. The sequencing service for this work was provided by the Norwegian Sequencing Centre (www.sequencing.uio.no) and the computations were performed on resources provided by Sigma2 - the National Infrastructure for High Performance Computing and Data Storage in Norway.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author contributions

FCP and KH conceived the study. All authors contributed to the design of the study and
interpretation of data. PR and KH included the infants, collected samples and patient metadata.
PR, GS and HAA processed the samples under FCP supervision. AD analysed shotgun
metagenomic data. AD and PR carried out statistical data analysis and created the figures. PR
and AD wrote the manuscript. All authors discussed the results, critically revised the
manuscript, and agreed to the published version of the manuscript.

Funding

This work was primarily funded by the Research Council of Norway (RCN) project numbers
273833 and 322375, and by the Olav Thon Foundation, with additional support from the Faculty
of Dentistry at the University of Oslo and by Oslo University Hospital.

References

1. Gallacher, D.J. & Kotecha, S. Respiratory Microbiome of New-Born Infants. *Front Pediatr* **4** (2016).

2. Staude, B. et al. The Microbiome and Preterm Birth: A Change in Paradigm with Profound Implications for Pathophysiologic Concepts and Novel Therapeutic Strategies. *BioMed research international* **2018**, 7218187 (2018).

3. Bosch, A. et al. Maturation of the Infant Respiratory Microbiota, Environmental Drivers, and Health Consequences. A Prospective Cohort Study. *American journal of respiratory and critical care medicine* **196**, 1582-1590 (2017).

4. Groer, M.W. et al. Development of the preterm infant gut microbiome: a research priority. *Microbiome* **2**, 38 (2014).

5. Selway, C.A., Collins, C.T., Makrides, M., Sullivan, T.R. & Weyrich, L.S. Variable preterm oral microbiome stabilizes and reflects a full-term infant profile within three months. *Pediatric research* (2023).

6. Biesbroek, G. et al. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. *Am J Respir Crit Care Med* **190**, 1283-1292 (2014).

7. Bosch, A. et al. Development of Upper Respiratory Tract Microbiota in Infancy is Affected by Mode of Delivery. *EBioMedicine* **9**, 336-345 (2016).

8. Dominguez-Bello, M.G. et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proceedings of the National Academy of Sciences of the United States of America* **107**, 11971-11975 (2010).

9. Biesbroek, G. et al. The impact of breastfeeding on nasopharyngeal microbial communities in infants. *American journal of respiratory and critical care medicine* **190**, 298-308 (2014).

10. Flynn, M. & Dooley, J. The microbiome of the nasopharynx. *J Med Microbiol* **70** (2021).

11. Gollwitzer, E.S. et al. Lung microbiota promotes tolerance to allergens in neonates via PD-L1. *Nat Med* **20**, 642-647 (2014).

12. Sharma, A.A., Jen, R., Butler, A. & Lavoie, P.M. The developing human preterm neonatal immune system: a case for more research in this area. *Clin Immunol* **145**, 61-68 (2012).

13. Liu, C. et al. Microbial dysbiosis and childhood asthma development: Integrated role of the airway and gut microbiome, environmental exposures, and host metabolic and immune response. *Frontiers in immunology* **13**, 1028209 (2022).

14. Teo, S.M. et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* **17**, 704-715 (2015).

15. Binia, A. et al. The Influence of FUT2 and FUT3 Polymorphisms and Nasopharyngeal Microbiome on Respiratory Infections in Breastfed Bangladeshi Infants from the Microbiota and Health Study. *mSphere* **6**, e0068621 (2021).

16. Toivonen, L. et al. Antibiotic Treatments During Infancy, Changes in Nasal Microbiota, and Asthma Development: Population-based Cohort Study. *Clinical Infectious Diseases* **72**, 1546-1554 (2021).

17. Man, W.H., de Steenhuijsen Piters, W.A. & Bogaert, D. The microbiota of the respiratory tract: gatekeeper to respiratory health. *Nature reviews. Microbiology* **15**, 259-270 (2017).

18. Kristensen, M. et al. The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children. *Cell Reports Medicine* **5** (2024).

19. Zelasko, S. et al. Early-life upper airway microbiota are associated with decreased lower respiratory tract infections. *Journal of Allergy and Clinical Immunology* **155**, 436-450 (2025).

20. Perin, J. et al. Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals. *Lancet Child Adolesc Health* **6**, 106-115 (2022).

21. Tracy, M.C. & Cornfield, D.N. Bronchopulmonary Dysplasia: Then, Now, and Next. *Pediatr Allergy Immunol Pulmonol* **33**, 99-109 (2020).

22. Harju, M. et al. The burden of childhood asthma and late preterm and early term births. *J*
Pediatr **164**, 295-299.e291 (2014).
23. Priante, E. et al. Respiratory Outcome after Preterm Birth: A Long and Difficult Journey. *Am J*
Perinatol **33**, 1040-1042 (2016).
24. Costello, E.K., Carlisle, E.M., Bik, E.M., Morowitz, M.J. & Relman, D.A. Microbiome assembly
across multiple body sites in low-birthweight infants. *mBio* **4**, e00782-00713 (2013).
25. Vatne, A. et al. Early Empirical Antibiotics and Adverse Clinical Outcomes in Infants Born Very
Preterm: A Population-Based Cohort. *J Pediatr* **253**, 107-114.e105 (2023).
26. O'Connor, L. & Heyderman, R. The challenges of defining the human nasopharyngeal
resistome. *Trends in Microbiology* **31**, 816-831 (2023).
27. Dhariwal, A. et al. Prolonged hospitalization signature and early antibiotic effects on the
nasopharyngeal resistome in preterm infants. *Nature Communications* **15**, 6024 (2024).
28. Rajar, P. et al. Microbial DNA extraction of high-host content and low biomass samples:
Optimized protocol for nasopharynx metagenomic studies. *Frontiers in microbiology* **13**,
1038120 (2022).
29. Andrews S. (2010). FastQC: a quality control tool for high throughput sequence data.
Available online at: http://www.bioinformatics.babraham.ac.uk/projects/fastqc.
30. Krueger, F. "Trim Galore: a wrapper tool around Cutadapt and FastQC." Trim Galore (2012).
31. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**,
357-359 (2012).
32. Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse
microbial communities with bioBakery 3. *Elife* **10**, e65088 (2021).
33. Allaire, J. RStudio: integrated development environment for R. *Boston, MA* **770**, 165-171
(2012).
34. R Core Team, R. R: A language and environment for statistical computing. (2013).
35. Wickham, H. ggplot2. *Wiley interdisciplinary reviews: computational statistics* **3**, 180-185
(2011).
36. Gasparrini, A.J. et al. Persistent metagenomic signatures of early-life hospitalization and
antibiotic treatment in the infant gut microbiota and resistome. *Nat Microbiol* **4**, 2285-2297
(2019).
37. Organization, W.H. in Executive summary: ending preventable child deaths from pneumonia
and diarrhoea by 2025: the integrated global action plan for pneumonia and diarrhoea
(GAPPD) (2013).
38. Gallacher, D. et al. Dissimilarity of the gut-lung axis and dysbiosis of the lower airways in
ventilated preterm infants. *The European respiratory journal* **55**, 1901909 (2020).
39. Lauer, T. et al. Bacterial Colonization within the First Six Weeks of Life and Pulmonary
Outcome in Preterm Infants <1000 g. *J Clin Med* **9** (2020).
40. Nurjadi, D. et al. Surveillance for colonization, transmission, and infection with methicillin-
susceptible Staphylococcus aureus in a neonatal intensive care unit. *JAMA network open* **4**,
e2124938-e2124938 (2021).
41. Organization, W.H. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public
health importance, to guide research, development, and strategies to prevent and control
antimicrobial resistance. (World Health Organization, 2024).
42. Shekhar, S. et al. Antibodies reactive to commensal Streptococcus mitis show cross-reactivity
with virulent Streptococcus pneumoniae serotypes. *Frontiers in Immunology* **9**, 747 (2018).
43. Lebon, A. et al. The inverse correlation between Staphylococcus aureus and Streptococcus
pneumoniae colonization in infants is not explained by differences in serum antibody levels
in the Generation R Study. *Clinical and Vaccine Immunology* **18**, 180-183 (2011).
44. de Steenhuijsen Piters, W.A. et al. Early-life viral infections are associated with
disadvantageous immune and microbiota profiles and recurrent respiratory infections.
Nature Microbiology **7**, 224-237 (2022).

45. Følsgaard, N.V. et al. Pathogenic bacteria colonizing the airways in asymptomatic neonates
stimulates topical inflammatory mediator release. *Am J Respir Crit Care Med* **187**, 589-595
(2013).
46. Man, W.H. et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota
until 6 years of life: a subanalysis of the MAKI randomised controlled trial. *Lancet Respir Med*
8, 1022-1031 (2020).
47. Zeng, Y. & Liang, J.Q. Nasal Microbiome and Its Interaction with the Host in Childhood
Asthma. *Cells* **11** (2022).
48. Bokulich, N.A. et al. Antibiotics, birth mode, and diet shape microbiome maturation during
early life. *Science translational medicine* **8**, 343ra382-343ra382 (2016).
49. Perez, G.F. et al. Nasopharyngeal microbiome in premature infants and stability during
rhinovirus infection. *J Investig Med* **65**, 984-990 (2017).
50. Reyman, M. et al. Microbial community networks across body sites are associated with
susceptibility to respiratory infections in infants. *Communications biology* **4**, 1233 (2021).
51. Aguilar-Lopez, M., Dinsmoor, A.M., Ho, T.T.B. & Donovan, S.M. A systematic review of the
factors influencing microbial colonization of the preterm infant gut. *Gut Microbes* **13**, 1-33
(2021).
52. Kelderer, F. et al. Associations between pre- and postnatal antibiotic exposures and early
allergic outcomes: A population-based birth cohort study. *Pediatr Allergy Immunol* **33**,
e13848 (2022).
53. Lu, Y. et al. Early-Life Antibiotic Exposure and Childhood Asthma Trajectories: A National
Population-Based Birth Cohort. *Antibiotics* **12**, 314 (2023).
54. Zimmermann, P. Exploring the microbial landscape of the nasopharynx in children: a
systematic review of studies using next generation sequencing. *Frontiers in Microbiomes* **2**,
1231271 (2023).
55. Murray, C.J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic
analysis. *The lancet* **399**, 629-655 (2022).
56. Salas Garcia, S. et al. Early-onset sepsis: a cohort study comparing serial clinical observation
with laboratory testing. *J Perinatol* **41**, 2482-2487 (2021).
57. Vatne, A. et al. Reduced Antibiotic Exposure by Serial Physical Examinations in Term
Neonates at Risk of Early-onset Sepsis. *Pediatr Infect Dis J* **39**, 438-443 (2020).
58. Parker, L.A. et al. Neonatal Feeding Tube Colonization and the Potential Effect on Infant
Health: A Review. *Frontiers in Nutrition* **9** (2022).
59. Hartz, L.E., Bradshaw, W. & Brandon, D.H. Potential NICU Environmental Influences on the
Neonate's Microbiome: A Systematic Review. *Adv Neonatal Care* **15**, 324-335 (2015).
60. Hourigan, S.K. et al. Comparison of Infant Gut and Skin Microbiota, Resistome and Virulome
Between Neonatal Intensive Care Unit (NICU) Environments. *Frontiers in Microbiology* **9**
(2018).
61. Cristina, M.L., Sartini, M. & Spagnolo, A.M. Serratia marcescens infections in neonatal
intensive care units (NICUs). *International journal of environmental research and public*
health **16**, 610 (2019).
62. Gibson, M.K. et al. Developmental dynamics of the preterm infant gut microbiota and
antibiotic resistome. *Nature microbiology* **1**, 1-10 (2016).
63. Thänert, R., Sawhney, S.S., Schwartz, D.J. & Dantas, G. The resistance within: antibiotic
disruption of the gut microbiome and resistome dynamics in infancy. *Cell host & microbe* **30**,
675-683 (2022).
64. Flannery, D.D. et al. Temporal trends and center variation in early antibiotic use among
premature infants. *JAMA network open* **1**, e180164-e180164 (2018).
65. Schwartz, D.J., Langdon, A.E. & Dantas, G. Understanding the impact of antibiotic
perturbation on the human microbiome. *Genome medicine* **12**, 1-12 (2020).
66. Kennedy, K.M. et al. Questioning the fetal microbiome illustrates pitfalls of low-biomass
microbial studies. *Nature* **613**, 639-649 (2023).

67. Luna, P.N. et al. The association between anterior nares and nasopharyngeal microbiota in
infants hospitalized for bronchiolitis. *Microbiome* **6**, 2 (2018).
68. Gloor, G.B., Macklaim, J.M., Pawlowsky-Glahn, V. & Egozcue, J.J. Microbiome Datasets Are
Compositional: And This Is Not Optional. *Frontiers in Microbiology* **8** (2017).
69. Knight, R. et al. Best practices for analysing microbiomes. *Nature Reviews Microbiology* **16**,
410-422 (2018).
70. Brooks, B. et al. Microbes in the neonatal intensive care unit resemble those found in the gut
of premature infants. *Microbiome* **2**, 1 (2014).
71. Ferretti, P. et al. Mother-to-infant microbial transmission from different body sites shapes
the developing infant gut microbiome. *Cell host & microbe* **24**, 133-145. e135 (2018).
72. Sampaio-Maia, B. & Monteiro-Silva, F. Acquisition and maturation of oral microbiome
throughout childhood: An update. *Dental research journal* **11**, 291 (2014).
73. Luoto, R. et al. Prebiotic and probiotic supplementation prevents rhinovirus infections in
preterm infants: a randomized, placebo-controlled trial. *The Journal of allergy and clinical*
immunology **133**, 405-413 (2014).
74. Kang, H.M. & Kang, J.H. Effects of nasopharyngeal microbiota in respiratory infections and
allergies. *Clinical and Experimental Pediatrics* **64**, 543 (2021).
75. Shekhar, S., Schwarzer, M., Dhariwal, A. & Petersen, F.C. Nasal microbiota transplantation: a
gateway to novel treatments. *Trends in Microbiology* (2025).

Figure 1. Patient inclusion and sample processing. (A) Flowchart describing patient inclusion process and availability of infants from birth until last follow up at six months corrected age. **(B)** Overview of obtained nasopharyngeal aspirate samples and excluded samples prior to main microbiome analysis. WMS: whole metagenomic sequencing.

Figure 2. Taxonomic composition of the nasopharyngeal microbiome. (A) Boxplot showing the total bacterial DNA (16S rRNA, ng), as measured by qPCR, for all infants across sampling time points spanning from birth to six months corrected age. Significant differences between time points were determined using a GLMM model that accounted for individual variation and age, followed by two-sided Tukey's HSD post hoc tests. **(B)** Comparison of bacterial load at each sampling time point among different antibiotic (AB) exposure groups, with differences tested using pairwise Wilcoxon rank-sum tests. In panels **(A)** and **(B)**, the central horizontal line in each boxplot represents the median, the box indicates the interquartile range (IQR), and the whiskers extend to 1.5× IQR. P-values were corrected using the Benjamini–Hochberg (BH) method (*$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, and ****$p < 0.0001$). **(C–F)** Stacked bar plots displaying the mean relative bacterial abundance of the 20 most abundant taxa across sampling time points and AB exposure groups at the genus **(C–D)** and species **(E–F)** levels. Panels **(C)** and **(E)** illustrate the mean relative bacterial abundance by sampling time point (x-axis), while panels **(D)** and **(F)** present the data stratified by both sampling time point and postnatal AB exposure group. Low abundant taxa (genus and species) are grouped into the "Others" category. GLMM: generalized linear mixed-effects model.

Figure 3: Effect of postnatal antibiotics on the nasopharyngeal microbial diversity, composition and stability. (A, B) Boxplots comparing species α-diversity (measured using the Shannon index) across sampling time points for all nasopharyngeal samples **(A)** and stratified

by postnatal antibiotic exposure group **(B)**. In these boxplots, the lower and upper horizontal line indicate the 25th and 75th percentiles, respectively, with the central line showing the median. Whiskers extend to the most extreme values within 1.5 times the interquartile range (IQR). Significant differences between time points were determined using a GLMM approach that corrected for individual variation and age, followed by two-sided Tukey's HSD post hoc tests. **(C, D)** Principal component analysis (PCA) plots based on Aitchison dissimilarities of CLR-transformed species abundances, visualizing the overall nasopharyngeal microbiome composition at time point 2 **(C)** and time point 3 **(D)**. Each data point represents one sample and is colored according to early **(C)** or late **(D)** antibiotic exposure, with ellipses representing the 95% confidence interval around the centroid of the microbiome composition for each group. Statistical significance, indicated by adjusted P-values (calculated using the Benjamini– Hochberg method) and effect sizes (R^2), was assessed using a PERMANOVA test and is displayed at the bottom right of each plot. **(E)** Boxplot comparing the changes in nasopharyngeal microbiota stability, calculated as the Aitchison distance between consecutive sampling time points within the same subjects, among the three antibiotic exposure groups. Pairwise Wilcoxon tests with Benjamini–Hochberg (BH) correction for multiple comparisons were performed. **(F)** Dot plot showing the stability of nasopharyngeal microbiota profiles over sampling time points stratified by postnatal antibiotic exposure. Stability was measured by calculating the Aitchison dissimilarity between each pair of consecutive time points for each infant. Loess lines were fitted to the data for each antibiotic exposure group, with shaded areas representing the 95% confidence intervals. In **A**, **B** and **E**, statistical significance is denoted by asterisks as follows: *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, and ****$p < 0.0001$. ns: not significant.

Figure 4. Nasopharyngeal microbiome composition of preterm infants evolves with age.

(A) Principal Component Analysis (PCA) plot of the overall nasopharyngeal microbiota

composition, based on CLR-transformed species abundances. Each point represents one sample

(n = 336), colored by age group (or sampling time point). Boxplots on the bottom and right

margins illustrate the distribution of samples along the first two principal components. In the

boxplots, the center line denotes the median, box edges mark the 25th and 75th percentiles

(interquartile range, IQR), and whiskers extend to $1.5 \times$ IQR. Adjusted p-values were calculated

using two-sided pairwise Wilcoxon tests with Benjamini–Hochberg (BH) correction (*$p < 0.05$;

$p < 0.01$; ***$p < 0.001$; ****$p < 0.0001$). **(B) Tenfold cross-validation error as a function of

the number of input species used to regress against infants' chronological age in the training

set. The results indicate that 24 species are sufficient for random forest–based predictions of

chronological age from the microbiota composition. Data are shown as the mean ± SEM from

100 iterations. **(C)** The 24 most informative, age-discriminatory bacterial species identified by

the random forest model, listed in descending order of their importance for model accuracy.

These species were included in a sparse model. Data are represented as the mean ± SEM from

100 iterations. **(D)** Scatterplot showing the relationship between chronological age and the

microbiome-predicted age (in months), with each dot representing a sample (n = 336). Dots are

colored by antibiotic exposure group. The line of best fit and its 95% confidence interval

(shaded area) were estimated by linear regression (Pearson's R = 0.97, $p < 0.0001$).

Figure 5: Identification of four community types in the nasopharyngeal microbiome of

preterm infants. **(A)** Dirichlet Multinomial Mixture (DMM) analysis clustered the 336

samples into four distinct clusters, which were visualized using Principal Component Analysis

(PCA) based on Aitchison distances of species composition. Each point represents a single

sample and is colored according to its community type. **(B)** Box plots show the relative

abundance of the main contributing taxa at the genus level within each community type. **(C)**

Boxplot of species diversity (Shannon index) in the nasopharyngeal microbiome samples of

preterm infants, grouped by the four identified community types. **(D)** Bar chart shows the

proportions of community types identified at different sampling time points across the whole cohort (left) and in three groups stratified according to postnatal antibiotic exposure (right) (n = 336). (**E)** The distribution of community types across the infant postnatal antibiotic exposure groups. (**F**) Stability and transition probabilities among the four microbial community types, evaluated *via* Markov Chain modelling across different antibiotic exposure groups. Each node represents a community type identified by the DMM model, and arrow width is proportional to the maximum likelihood estimate of transition probabilities among the community types. **(G)** Boxplots comparing the antibiotic resistance gene (ARG) diversity (Shannon index, left) and total ARG abundance (sum of RPKM, right) in nasopharyngeal samples (n = 336) from preterm infants, stratified by community types. In **B, C**, and **G**, the horizontal lines in each boxplot represent the first quartile, the median, and the third quartile. Pairwise Wilcoxon rank-sum tests with Benjamini–Hochberg (BH) correction were used to assess statistical significance. $*p < 0.05$, $**p < 0.01$, $***p<0.001$ and $****p < 0.0001$. ns: not significant; CT: community type.

Figure 6: *S. marcescens* outbreak at the NICU. (A) Samples are shown in chronological order by sampling date. Each bar represents one sample, grouped by whether the infant was discharged or transferred to a different NICU before the outbreak, or hospitalized and discharged from the NICU after the outbreak. The relative abundance of *S. marcescens* is shown in blue, while the abundance of all other bacterial species is combined into the "Others" category (gray). **(B)** Boxplots illustrating the CLR-transformed abundance of *S. marcescens* across different postnatal antibiotic exposure groups at each time point (1–6). The line within each box denotes the median, the box edges represent the 25th and 75th percentiles, and whiskers extend to 1.5× the interquartile range. **(C)** PCA plot of the nasopharyngeal microbiota, colored according to the CLR-transformed abundance of *S. marcescens*. Points shaded in blue indicate higher *S. marcescens* abundance; points in gray indicate lower abundance. Gradient

values are shown in the legend on the right. **(D)** Boxplots of the CLR-transformed and relative

abundance (%) of *S. marcescens* in samples collected from birth to six months corrected age.

Samples are grouped by hospitalization status (discharged/moved to a different NICU before

the outbreak vs. hospitalized and discharged after the outbreak). Statistical significance of

differences was determined using two-sided pairwise Wilcoxon rank-sum tests with

Benjamini–Hochberg (BH) correction. Statistically significant differences are denoted with

asterisks: $*p < .05$, $**p < .01$, $***p < .001$ and $****p < .0001$; ns: not statistically significant.

(E) PCA plot based on Aitchison dissimilarities (species level) of all nasopharyngeal samples

collected from birth to six months corrected age. Each point represents a sample, colored red if

collected from infants discharged or moved before the outbreak and blue if from those

hospitalized and discharged afterward. Effect sizes (R^2) and corresponding adjusted p-values

(p.adj, BH-corrected) were calculated using PERMANOVA, as shown in the bottom left of the

plot. Percentages on the axes indicate the variance explained by each principal component.

PCA: principal component analysis; PERMANOVA: permutational multivariate analysis of

variance; *p.adj*: adjusted *p*-values.

Figure S1: Overview of obtained samples and sampling time points in our study cohort. **(A)**

Nasopharyngeal aspirate (NPA) samples collected from each infant (left y-axis) are connected

by horizontal lines. Infants are organized by postnatal antibiotic (AB) exposure (right y-axis).

The x-axis represents the day of life (DOL). In total, 369 NPA samples were obtained from 66

infants within the first six months of corrected age. **(B)** NPA samples were collected at six

designated sampling time points (y-axis). If a sample could not be obtained according to the

protocol at the designated time (e.g., if the infant was unstable), a new sample was collected as

soon as possible, leading to greater variation in DOL for each time point. The horizontal bars

indicate the DOL range for each sampling time, and the vertical line within each bar denotes

the mean. Mean (SD) values are listed on the right side of the figure. **(C)** Scatter plot showing

the correlation between bacterial abundance measured by qPCR (log 16S qPCR [ng]) on the x-

axis and bacterial read counts (in millions) from metagenomic sequencing on the y-axis. Each

dot represents a single sample. R = Pearson's correlation coefficient.

Figure S2: Stacked bar plots showing the mean relative abundances of the five most abundant

bacterial phyla by sampling time point (left) and by antibiotic (AB) exposure group (right)

across the sampling period. All other phyla with mean relative abundances <1% are grouped

into the "Others" category.

Figure S3: Principal Component Analysis (PCA) plots, based on Aitchison dissimilarity,

visualizing the overall nasopharyngeal microbial community composition of preterm infants at

each sampling time point **(A–F)**. Each point represents a sample and is colored according to the

postnatal antibiotic (AB) exposure group. Ellipses represent the 95% confidence interval for

each AB exposure group. Effect sizes (R^2) from permutational multivariate analysis of variance

(PERMANOVA), along with corresponding adjusted P-values (*p.adj*, calculated using the

Benjamini–Hochberg method), are shown at the bottom right of each plot.

Figure S4: Boxplots illustrating the temporal stability of the nasopharyngeal microbiota,

stratified by postnatal antibiotic exposure. Aitchison dissimilarities between consecutive time

points (1–2, 2–3, 3–4, 4–5, and 5–6) within each subject were used as a measure of stability.

The horizontal line in each box indicates the median, while the lower and upper box boundaries

correspond to the 25th and 75th percentiles, respectively. Whiskers extend to the most extreme

data points within $1.5 \times$ IQR of the box boundaries. Brackets highlight statistically significant

differences between time points within each group (Adjusted P-values (*p.adj*) < 0.05; pairwise

Wilcox test), with **p.adj* < 0.05, ***p.adj* < 0.01, and ****p.adj* < 0.001.

Figure S5: Individual variability and postnatal age significantly influence the nasopharyngeal microbiome composition in preterm infants. Principal Component Analysis (PCA) plots (based on CLR-transformed species abundance) illustrate β-diversity of the nasopharyngeal microbiota. Panels **(A)**, **(B)**, and **(C)** show the effects of individual variability, postmenstrual age (PMA), and days of life (DOL), respectively. Each point represents one patient sample (n = 336), color-coded according to the relevant grouping (individual, PMA, or DOL). Effect sizes (R^2) and corresponding adjusted P-values (*p.adj*, Benjamini–Hochberg correction) were calculated using PERMANOVA and are displayed in the bottom left of each plot.

Figure S6: Dirichlet multinomial mixture (DMM) analysis of nasopharyngeal samples reveals four distinct community types. **(A)** The Laplace approximation from the DMM fit indicates four optimal nasopharyngeal microbiota structures in our preterm infant cohort, and (B) shows the top 10 driver species for each DMM-based community type, ordered by their assignment strength on the y-axis.

Figure S7. (A) Overview of the 13 NICU infants (y-axis) screened at least once during the two main screening days (x-axis). Within a few days of receiving a negative screening result, nine infants were found to have reads assigned to *S. marcescens*, including four with a lower relative abundance (<1.3%) and five with a higher relative abundance (16.5–85.0%). **(B)** Timeline of *S. marcescens* detection in nasopharyngeal samples from each preterm infant across multiple time points, where each point represents a sample, colored by whether it was collected before or after the outbreak detection, and point shapes indicate whether *S. marcescens* was identified in whole metagenomic analyses. **(C)** Principal Components Analysis (PCA) plots of β-diversity (Aitchison distances) at each time point (1–6), with each point representing a sample and colored by whether it was collected before or after the outbreak. Adjusted p-values (Benjamini–

Hochberg correction) and effect sizes (R^2) for all time points were calculated using

PERMANOVA and summarized in the panel on the right.

Figure S8. Random Forest confusion matrices for classifying preterm infants at six months

corrected age as *S. marcescens* persistence or non-persistence, based on nasopharyngeal

microbiota composition at time points 1 **(A)** and 2 **(B)**. Panels **(C)** and **(D)** show the top 10

species that most strongly contributed to the classification at time points 1 and 2, respectively.

Tables

Whole cohort (n=66)	AB naive (n=21)	AB exposed (n=45)	Only early ABs (n=24)	Other ABs (n=21)
Male, n (%)	12 (57%)	33 (73%)	18 (75%)	15 (71%)
GA, weeks (mean, SD)	31, 6/7	**29 4/7, 1 ****	**29 4/7, 1 ****	**29 3/7, 1 ****
BW, grams (mean, SD)	1562, 188	**1280, 262 ****	**1278, 255 ****	**1282, 275 ****
BW, group, n (%)		*	*	*
ELBW	0 (0%)	**6 (13%)**	**3 (12%)**	**3 (14%)**
VLBW	8 (38%)	**31 (69%)**	**17 (71%)**	**14 (67%)**
LBW	13 (62%)	**8 (18%)**	**4 (17%)**	**4 (19%)**
Vaginal delivery n (%)	4 (19%)	**16 (35.5%)**	**9 (37.5%)**	**8 (38%)**
Caesarian section, n (%)	17 (81%)	29 (64.5%)	15 (62.5%)	13 (62%)
ABs during pregnancy, n (%)				
None	21 (100%)	**32 (71%) ***	**13 (54%) ****	19 (90%)
< 10 days	0 (0%)	10 (22%)	10 (42%)	0 (0%)
≥10days	0 (0%)	3 (7%)	1 (4%)	2 (10%)
Intrapartum AB prophylaxis, n (%)				
None documented	2 (10%)	3 (7%)	1 (4%)	2 (10%)
Given	19 (90%)	42 (93%)	23 (96%)	19 (90%)
ROM, hours (means, SD)	3, 12	201, 491	**258, 422 ***	136, 563

Apgar at 10 min (mean, SD)	9, 1	9, 1	8, 1	9, 1
Nutrition, n (%)				
Fully breastfed	7 (39%)	13 (30%)	5 (22%)	8 (40%)
> 50% MOM	3 (17%)	11 (26%)	7 (30%)	4 (20%)
> 50% formula	6 (33%)	8 (18%)	5(22%)	3(15%)
Only formula	2 (11%)	11 (26%)	6 (26%)	5 (25%)
Lost to follow up	3 (14%)	2 (4%)	1 (4%)	1(5%)

929 **Table 1. Cohort demographics.** AB: antibiotic; GA: gestational age; BW: birth weight; LBW:

930 low birth weight (from 1500g to < 2500g); VLBW: very low body weight (from 1000g to <

931 1500g); ELBW: extremely low body weight (< 1000g); ROM: rupture of membranes; MOM:

932 mothers' own milk. * $p<0.05$, ** $p<0.001$.